Medical Marketing International Group

Medical Marketing International Group (MMI) was a prominent United Kingdom-based life sciences technology transfer and investment firm that specialized in the commercialization of early-stage biomedical research. Founded in 1988 and headquartered in Cambridge, the company functioned as an incubator, providing essential seed capital, strategic management, and intellectual property expertise to spin-out ventures from academic institutions. MMI's portfolio was notably strong in molecular diagnostics and drug development services, with its most significant success being the development of OncoMethylome Sciences (now MDxHealth). The group was publicly traded on the London Stock Exchange's AIM market until its acquisition by The Medical House plc in 2006. MMI played a critical role in bridging the gap between laboratory discoveries and the global pharmaceutical market during its years of operation.